Diadema Partners LP Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN

Diadema Partners LP lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 42.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,607 shares of the biopharmaceutical company’s stock after selling 4,221 shares during the quarter. Regeneron Pharmaceuticals makes up 0.9% of Diadema Partners LP’s portfolio, making the stock its 27th largest holding. Diadema Partners LP’s holdings in Regeneron Pharmaceuticals were worth $2,944,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of REGN. Activest Wealth Management raised its holdings in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the period. Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Colonial Trust Advisors bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $32,000. SouthState Corp lifted its position in shares of Regeneron Pharmaceuticals by 550.0% during the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 44 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research analyst reports. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Sanford C. Bernstein lifted their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Morgan Stanley cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $767.00 target price for the company. in a research note on Wednesday, December 3rd. Finally, Truist Financial began coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a “buy” rating and a $798.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $777.36.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $692.58 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $791.49. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $656.15 and a 200-day moving average price of $589.72. The firm has a market capitalization of $72.79 billion, a PE ratio of 16.58, a price-to-earnings-growth ratio of 2.01 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the prior year, the company posted $12.46 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Insiders Place Their Bets

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.